Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Rutgers, The State University of New Jersey
Valerio Therapeutics
Valerio Therapeutics
Dartmouth-Hitchcock Medical Center
Case Comprehensive Cancer Center